#BMS #Cobenfy #Schizophrenia #Neuroscience #Psychiatry #PharmaNews #DrugDevelopment #Opdivo #Camzyos #AlzheimersDisease #Innovation #Healthcare #Biopharma To view or add a comment, sign in Market Watch | Bristol Myers Squibbs Cobenfy Faces Uptake Challenges Amid Strong Q3 Earnings Bristol Myers Squibb ($BMY) reported $12.2B in Q3 revenue, surpassing analyst expectations yet investor attention centered on Cobenfy, the first new schizophrenia drug in 35 years, which posted $43M in sales, slightly below forecasts
If each drink provides less reward than it used to, motivation to have additional drinks decreases
This is long by peptide standards
TrimRx understands these unique preferences
At 15mg weekly, participants lost 22.5% on average, about 52 pounds (24 kg)
I feel like a lot of people have this stigma on GLP-1s and say things like, Oh, lazy people do it, or If youre working hard enough, you dont need that, she shares